Aptamer targeting the ERBB2 receptor tyrosine kinase for applications in tumor therapy

Methods in Molecular Biology

Volumn 1317, Issue , 2015, Pages 3-15

  Mahlknecht, Georg ^a   Sela, Michael ^a   Yarden, Yosef ^a  

^a NONE

Author keywords

Aptamer; Degradation; ERBB2 HER2; Gastric cancer; Targeted therapy; Tumor

Indexed keywords

ANTIBODY; APTAMER; BUFFER; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOTTING; CELL PROLIFERATION ASSAY; COMPARATIVE STUDY; CONTROLLED STUDY; DNA LIBRARY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; IN VIVO STUDY; LYSOSOME; MOLECULAR CLONING; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; TUMOR XENOGRAFT; WESTERN BLOTTING; XTT ASSAY; ANIMAL; CELL PROLIFERATION; COMBINATORIAL CHEMISTRY; DNA SEQUENCE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; NEOPLASMS; NUDE MOUSE; PROCEDURES; TUMOR CELL LINE;

ANIMALS; APTAMERS, NUCLEOTIDE; BASE SEQUENCE; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CLONING, MOLECULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MICE, NUDE; NEOPLASMS; RECEPTOR, ERBB-2; SELEX APTAMER TECHNIQUE; SEQUENCE ANALYSIS, DNA;

EID: 84931272563     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-2727-2_1     Document Type: Article

References (19)

1. Köhler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256(5517):495–497
2. Ben-Kasus T, Schechter B, Sela M, Yarden Y (2007) Cancer therapeutic antibodies come of age: targeting minimal residual disease. Mol Oncol 1(1):42–54
3. Mahlknecht G, Maron R, Mancini M, Schechter B, Sela M, Yarden Y (2013) Aptamer to ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growth. Proc Natl Acad Sci U S A 110(20):8170–8175
4. Stoltenburg R, Reinemann C, Strehlitz B (2007) SELEX- (r)evolutionary method to generate high-affinity nucleic acid ligands. Biomol Eng 24:381–403
5. Ellington AD, Szostak JW (1990) In vitro selection of RNA molecules that bind specific ligands. Nature 346:818–822
6. Tuerk C, Gold L (1990) Systematic evolution of ligands by exponential enrichment of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249:505–515
7. Tombelli S, Minunni M, Mascini M (2005) Analytical applications of aptamers. Biosens Bioelectron 20:2424–2434
8. Hermann T, Patel DJ (2000) Adaptive recognition by nucleic acid aptamers. Biochemistry 287:820–825
9. Guo KT, Paul A, Schichor C, Ziemer G, Wendel HP (2008) CELL-SELEX: novel perspectives of aptamer-based therapeutics. Int J Mol Sci 9:668–678
10. Citri A, Yarden Y (2006) EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7:505–516
11. Rowinsky EK (2004) The ErbB Family: targets for therapeutic development against cancer and therapeutic Strategies using monoclonal antibodies and tyrosine kinase inhibitors. Annu Rev Med 55:433–457
12. Chen CH, Chernis GA, Hoang VQ, Landgraf R (2003) Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3. Proc Natl Acad Sci USA 105:15908–15913
13. Dastjerdi K, Tabar GH, Dehghani H, Haghparast A (2011) Generation of an enriched pool of DNA aptamers for a HER2- overexpressing cell line selected by Cell- SELEX. Biotechnol Appl Biochem 58(4): 226–230
14. Esposito CL, Passaro D, Longobardo I, Condorelli G, Marotta P, Affuso A, De Franciscis V, Cerchia L (2011) A neutralizing RNA aptamer against EGFR causes selective apoptotic cell death. PLoS One 6(9):e24071
15. Kang HS, Huh YM, Kim S, Lee D (2009) Isolation of RNA aptamers targeting HER-2- overexpressing breast cancer cells using Cell- SELEX. Bull Korean Chem Soc 30(8): 1827–1831
16. Kim MY, Jeong S (2011) In vitro Selection of RNA aptamer and specific targeting of ErbB2 in breast cancer cells. Nucleic Acid Ther 21(3):173–178
17. Li N, Nguyen HH, Byrom M, Ellington AD (2011) Inhibition of cell proliferation by an anti-EGFR aptamer. PLoS One 6(6):e20299
18. Thiel KW, Hernandez LI, Dassie JP, Thiel WH, Liu X, Stockdale KR, Rothman AM, Hernandez FJ, McNamara JO 2nd, Giangrande PH (2012) Delivery of chemo-sensitizing siRNAs to HER2+− breast cancer cells using RNA aptamers. Nucleic Acids Res 40(13): 6319–6337
19. Missailidis S (2003) Targeting of antibodies using aptamers. In: Lo BKC (ed) Antibody engineering: methods and protocols, vol 51. Humana Press, New York, pp 547–555